Allergy Therapeutics (LON:AGY) will deliver data from an efficacy study for Acarovac, its dust mite allergy treatment, at a major conference in Amsterdam starting today.
Acarovac has been Allergy’s strongest growing treatment in Spain this year and is part of a new generation of products for the perennial allergy market.
Allergy is the host the Eighth Annual Adjuvants in Allergy Conference at which Dr Albert Roger, from the allergy unit at the Universitari Hospital Germans Trias Pujol in Spain will present the data from the study.
Manuel Llobet, Allergy’s chief executive, added it was proud to host the conference, which was a highly scientific open forum to discuss allergy topics with expert key opinion leaders and allergists from around the world.
“The aim of the conference is to encourage the medical community to consider innovative solutions for patients suffering from allergies," he added.
Allergy has had a flurry of good news recently culminating in US clearance to resume a clinical programme to trial hay fever treatment Pollinex Quattro ahead of a possible market launch in 2019.